Showcases Stock ranks Forex

Aveo Pharmaceuticals (AVEO)
8.01  0.23 (2.96%) 08-08 16:00
Open: 7.95 Pre. Close: 7.78
High: 8.09 Low: 7.8
Volume: 306,308 Market Cap: 277M
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 8.095 - 8.119 8.119 - 8.146
Low: 7.728 - 7.757 7.757 - 7.789
Close: 7.958 - 8.003 8.003 - 8.052
Stock Technical Analysis
Target: Six months: 9.58
One year: 11.19
Support: Support1: 7.09
Support2: 6.40
Resistance: Resistance1: 8.20
Resistance2: 9.58
Pivot: 7.17
Moving Averages: MA(5): 7.61
MA(20): 7.11
MA(100): 5.52
MA(250): 5.45
MACD: MACD(12,26): 0.41
Signal(12,26,9): 0.38
%K %D: %K(14,3): 84.19
%D(3): 81.86
RSI: RSI(14): 74.87
52-Week: High: 8.2
Low: 3.06
Change(%): 33.1
Average Vol(K): 3-Month: 228
10-Days: 255
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ AVEO ] has closed Bollinger Bands are 5.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sun, 07 Aug 2022
AVEO Pharmaceuticals (NASDAQ:AVEO) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

Sat, 30 Jul 2022
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Forecasted to Post Q2 2022 Earnings of ($0.24) Per Share - Defense World

Fri, 29 Jul 2022
AVEO Pharmaceuticals (AVEO) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Wed, 22 Jun 2022
Should Biotechnology Stock AVEO Pharmaceuticals, Inc. (AVEO) Be in Your Portfolio Wednesday? - InvestorsObserver

Mon, 06 Jun 2022
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting - GlobeNewswire

Tue, 24 May 2022
AVEO Pharmaceuticals Stock Is Primed For A Breakout (NASDAQ:AVEO) - Seeking Alpha

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 34.48
Shares Float (M) 27.62
% Held by Insiders 0.19
% Held by Institutions 38.89
Shares Short (K) 1170
Shares Short Prior Month (K) 1070
Stock Financials
EPS -1.200
Book Value (p.s.) 0.890
Profit Margin -45.72
Operating Margin -39.90
Return on Assets (ttm) -18.7
Return on Equity (ttm) -79.6
Qtrly Rev. Growth 234.9
Gross Profit (p.s.) 0.327
Sales Per Share 2.292
EBITDA (p.s.) -0.913
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)
Stock Valuation
PE Ratio -6.67
PEG Ratio
Price to Book value 9.00
Price to Sales 3.49
Price to Cash Flow
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android